Avenue Therapeutics
ATXI
ATXI was delisted on the 18th of March, 2025.
11 hedge funds and large institutions have $849K invested in Avenue Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
427% more capital inflows, than outflows
Capital inflows: $362K | Capital outflows: $68.7K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.38% less ownership
Funds ownership: 9.58% → 9.2% (-0.38%)
15% less funds holding
Funds holding: 13 → 11 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$300K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.2K |
| 3 |
Shikiar Asset Management
New York
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Icon Wealth Advisors
Houston,
Texas
|
-$46.6K |
| 2 |
Renaissance Technologies
New York
|
-$19K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$2.64K |
| 4 |
Bank of New York Mellon
New York
|
-$494 |
ATXI Hedge Fund Activity: Q2 2023 in Review
11 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics (ATXI) for Q2 2023, worth a combined $849K — up 59% from $533K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ATXI and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $300K. The largest seller was Icon Wealth Advisors, exiting entirely with an estimated $46.6K sold.
- 11 institutional investors held Avenue Therapeutics (ATXI) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $849K of Avenue Therapeutics stock for Q2 2023, up 59% quarter-over-quarter.
- 0 funds opened new Avenue Therapeutics positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Avenue Therapeutics buyer in Q2 2023 was Sabby Management, an estimated $300K added.
- The largest Avenue Therapeutics seller in Q2 2023 was Icon Wealth Advisors, an estimated $46.6K sold.
Based on aggregated 13F filings for Q2 2023.